Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Effectiveness of Dolutegravir-Based Regimens as Either First Line or Switch Antiretroviral Therapy: Data from the ICONA Cohort
22 Pages Posted: 17 Sep 2018
More...Abstract
Background We aimed to estimate the risk of discontinuation (TD) and virological failure (VF) of dolutegravir (DTG)-based regimens.
Methods We performed a multicentre, observational study including all antiretroviral therapy (ART)-naïve and virologically suppressed treatment-experienced (TE) patients from the ICONA cohort who started DTG for the first time. We estimated time to DTG-TD and VF using Kaplan-Meier curves. We used Cox regression model to assess predictors of DTG-TD.
Findings 1,679 individuals (932 ART-naive, 747 TE) included. The one- and two-year probabilities (95% CI) of DTG-TD were 6⋅7% (4⋅9-8⋅4) and 11⋅5% (8⋅7-14⋅3) for ART-naive and 6⋅6% (4⋅6-8⋅6) and 7⋅6% (5⋅4-9⋅8) for TE subjects. In both ART-naive and TE, DTG-TD was mainly driven by toxicity with an estimated risk (95% CI) of 4⋅0% (2⋅6-5⋅4) and 2⋅5% (1⋅3-3⋅6) by one year and 5⋅6% (3⋅8-7⋅5) and 4⋅0% (2⋅4-5⋅6) by two years, respectively. Neuropsychiatric events were the main reason for DTG-TD in both ART-naive (2⋅1%) and TE (1⋅7%) patients. In ART-naive, a concomitant AIDS diagnosis predicted the risk of DTG-TD for any reason (aRH=3⋅38, p=0⋅001) whereas starting DTG in combination with abacavir (ABC) predicted DTG-TD for toxicity (aRH=3⋅30, p=0⋅009). TE patients starting a DTG-based dual therapy compared to a triple therapy had a lower risk of DTG-TD for any reason (aHR 2⋅50, p=0⋅037 for ABC-based triple-therapies, aHR 3⋅56, p=0.012 for tenofovir-based) and for toxicity (aHR 5⋅26, p=0⋅030 for ABC-based, aHR 6⋅60,p=0.024 for tenofovir-based). The one- and two-year probabilities (95% CI) of VF were 1⋅2% (0⋅3-2⋅0) and 4⋅6% (2⋅7-6⋅5) in the ART naive group and 2⋅2% (1⋅0-3⋅3) and 2⋅9% (1⋅5-4⋅3) in the TE group.
Interpretation DTG showed excellent efficacy and tolerability both in ART-naive and TE patients. The low risk of toxicities limiting DTG treatment provide reassuring information in the light of the forthcoming transition to DTG-based first-line therapy in resource-limited countries.
Funding: Viiv Healthcare International.
Declaration of Interest: AM, ACL, AT, FM and FV have nothing to disclose. SR outside the submitted work reports grants personal fees and non-financial support from ViiV Healthcare,Gilead Sciences and Janssen-Cilag, personal fees and non-financial support from Bristol Myers Squibb and personal fees from Merck Sharp and Dohme. FCS outside the submitted work reports personal fees from Gilead Sciences, Bristol Meyers Squibb, Abbvie, Roche Diagnostic, Janssen-Cilag, Abbott Molecular and ViiV Healthcare, grants and personal fees from Merck Sharp and Dohme and grants from Italian Ministry of Instruction University and Research. AC outside the submitted work reports grants and personal fees from ViiV Healthcare and personal fees from Merck Sharp and Dohme and Janssen-Cilag. ADL outside the submitted work reports grants and personal fees from ViiV 331 Healthcare, Merck Sharp and Dohme and Gilead Sciences and personal fees from Janssen-Cilag and Abbvie. GM outside the submitted work reports personal fees from Gilead Sciences and ViiV Healthcare. AA outside the submitted work reports grants, personal fees and non-financial support from Gilead Sciences, ViiV Healthcare and Bristol Myers Squibb, grants and personal fees from Janssen-Cilag, personal fees from Merck Sharp and Dohme and personal fees and non financial support from Abbvie. AdAM outside the submitted work reports grants and personal fees from Gilead Sciences, ViiV Healthcare and Merck Sharp and Dohme and personal fees from Janssen and Bristol Myers Squibb.
Ethical Approval: The Icona Foundation study was approved by the Ethics Committee (IRB) of each participating institution. All of the individuals enrolled provided a written informed consent at the time of the enrolment. All procedures of the study were performed in accordance with the 1964 Helsinki declaration and its later amendments.
Keywords: Antiretroviral therapy, dolutegravir, cohort study discontinuation, toxicity, adverse events, naive
Suggested Citation: Suggested Citation